Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: Initiative for standardizing guidelines

This article surveyed oncologists on measurable residual disease (MRD) testing in multiple myeloma, revealing inconsistent adoption and variability influenced by physician specialty, not location. While flow cytometry is preferred, negativity thresholds vary. MRD primarily guides treatment globally but is used more for patient discussion in the U.S.. Barriers include unavailability, lack of standardized guidelines, and financial constraints. Standardization and improved accessibility are needed to optimize patient outcomes.